Pharmaceutical Executive
July 13, 2018
Columns
38
7
The role of insurance and risk management in protecting middle-market distributors from the growing opioid multi-district litigation (MDL).
July 13, 2018
Features
38
7
Outlining a real-world example in which building and operationalizing a patient- and customer-centric commercialization strategy drove a successful launch from a “standing start.”
July 10, 2018
Features
38
7
Pharm Exec convenes an expert panel at CBI’s Pharmaceutical Compliance Congress to discuss new ways to navigate the many complexities when it comes to the crucial task of assessing business and risk in the life sciences.
July 10, 2018
Features
38
7
While the field of regenerative medicine has grown considerably since the ’90s-in innovation and acceptance-entrenched companies such as Athersys are looking to forge new advances in the stem cell arena by transforming promising science into real-world treatments.
July 09, 2018
From the Editor
38
7
With blockchain still in the potential but not proven area of the pharma enterprise, when is the technology the right choice for you?
July 08, 2018
Columns
38
7
How navigating compliance risks requires so much more than policies and procedures.
July 07, 2018
Columns
38
7
Streamlined clinical research, more guidance speed new cures to patients.
July 07, 2018
Columns
38
7
Exploring the prospects-and related challenges-for Chinese life science as it aggressively pursues new growth areas.
July 01, 2018
Special Sponsored Section
38
7
The Indian pharmaceutical industry is traditionally known as a global powerhouse for the production of bulk drugs and generics, but less heralded is the growth India has made on the pharma world stage in several other areas, including biotechnology and R&D.
July 01, 2018
Issue PDF
38
7
Click the title above to open the Pharmaceutical Executive July 2018 issue in an interactive PDF format.